In his first address to staffers at HHS since becoming secretary of the department on Feb. 13, Robert F. Kennedy Jr. Tuesday ...

Senate committee members heard arguments on a bill that would place a 10-year pause on administering mRNA vaccines in Idaho ...

Health care providers say that hesitation and outright resistance to vaccines have become disturbingly common even in ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Vermont has the second lowest state fatality rate in the US (145.3 per 100K; Hawaii 112.6/100K). Mississippi (461.9/100K) and ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...